Student name
University
NURS-FPX4015
Professor’s Name
Submission Date
Comprehensive Head-to-Toe Assessment
Hello All. I am [Student Name]. It is an evaluation that entails a full body examination whose results provide a comprehensive and systematic report of the general health condition of a patient. It begins by inspection and palpation and proceeds to the assessment of each body system and does not leave any detail behind. The method assists in catching the fine changes in time, fosters the comprehensive knowledge, and allows interventions at an early stage. In the end, this is an evaluation that deals with effective personalized care planning.
Conducts Accurate Patient Assessment
Ivy Jackson, a 61-year old woman, complains of constant tiredness, feeling down and demotivated following the break-up of her 38-year marriage. Thorough examination reveals that she meets the criteria of major depressive disorder, and her symptoms follow an emotional, psychological, and physical pattern. Since her husband has left, she has experienced insomnia, unintended weight loss, pleasure deficit in activities, and heightened anxiety (Bains & Abdijadid, 2025). She has a significant medical history of hypertension and previous history of depression. The assessment touched on her psychosocial background, recent stress factors, support, current and past drug use, and mental status examination, which indicated a radiating depression symptom that not only needs medication control but also psychotherapy.
A full thyroid panel and vitamin D were also examined, and the results were within normal limits to exclude any biological reasons behind depression. At this stage, Ivy was diagnosed with a severe depressive disorder and was prescribed the use of escitalopram, a selective serotonin reuptake inhibitor. She was informed about the desired effects, the pharmacology and side effects of the drug (Landy et al., 2025). Although she did not show significant improvement in mood after two weeks of treatment, Ivy claimed that she slept better with melatonin and felt a bit more active in life, which is early medication response. Even though she has not started on individual therapy, she showed some initiative by attending meditation classes with her daughter, which indicates a slow but positive behavioral change. This highlights the need to enhance compliance and provide psychoeducation and support on a regular basis.
To provide a comprehensive and individualized care plan, nurses will need to keep observing the symptoms in Ivy, enhance therapeutic interactions, and facilitate treatment compliance. Additional interventions, like cognitive behavioral therapy (CBT) or interpersonal therapy (IPT), can help resolve the unresolved grief in Ivy, interpersonal tensions, and the cognitive distortions, which should be encouraged (Srivastava et al., 2024). Her past, present emotional suffering, and family support system give us the necessary background to formulate interventions to achieve long-term recovery and avoid relapse in the future.
Explains Diagnosis and Findings
During our physical examination, I noted that your movements and speech are slowed down and we refer to this as psychomotor retardation. You have also lost approximately ten pounds in the last couple of weeks without even trying and you have informed me you wake up a few times every night and find it difficult to get back to sleep. Your affect was quite flat when we assessed it and you have mentioned that you feel sad most of the day and have reported a consistent lack of energy and motivation. These are all significant signs since they reflect the behavioral, appetite and sleep changes we observe to determine mood disorders.
We can contrast our findings with the diagnostic criteria of MDD by combining what we have seen, your slowed movements, unintentional weight loss and disturbed sleep with what you have told us, that is, persistent sadness, loss of interest in activities, and fatigue. That is, we are trying to find a combination of symptoms, which have a minimum duration of two weeks, and adequately interfere with the ability to live normally (Bains & Abdijadid, 2025). We also rule out other health problems which may otherwise present themselves as depression using your typical thyroid and vitamin D. This is an important step because it will help us to be sure that your symptoms are not a result of some other potential underlying physical complications, and it is something that will allow us to focus our treatment effort on depression.
When I make these findings known to you, I would like you to understand that what you are experiencing is a known medical condition and it is not your fault. I explain how the slowed movements and sleeping difficulties are common in depression as brain chemicals like serotonin and norepinephrine that keep people in a good mood and energetic are imbalanced (Cui et al., 2024). Your weight changes in connection not only with the changes in your appetite but also with the way your body deals with energy in response to stress. Viewing every observation in terms of changes in body chemistry and brain functioning, not your weakness, gives you the proper context, which makes you feel enabled to participate in your treatment plan, as well as being exactly sure what we are collaborating on together.
Discusses Pharmacological Treatment Options
The most common initial pharmacotherapy of MDD is directed to SSRIs, namely escitalopram, sertraline, and fluoxetine, SNRIs, such as venlafaxine or duloxetine. Older adults may be treated with bupropion or mirtazapine where fatigue or sleep disturbance is the major concern. All these agents produce their effects by enhancing monoamine neurotransmission, therefore, they are effective in stabilizing mood and modulating energy levels over weeks (Kukucka et al., 2024). As long as monotherapy is not regarded as sufficient, it can be supplemented by low dose of atypical antipsychotics, lithium, or regulation. The current best practices in treatment choice should include starting low-dose treatment in elderly patients and monitoring efficacy and tolerability in acute treatment, continuation and maintenance.
The pharmacologic plan is informed by Ivy and her comorbid hypertension, which is treated with lisinopril and hydrochlorothiazide, her age and history of discontinuation syndrome with venlafaxine. There are not numerous cardiovascular interactions of SSRIs, however, they may cause hyponatremia, especially when combined with diuretics; she should have her sodium monitored regularly. Escitalopram also has a few interactions with the cytochrome P450 that is considered in its safety considering her current regimen unlike SNRIs that can elevate blood pressure thus it is advised to avoid their use (Chu & Wadhwa, 2025). Her successful toleration of melatonin as a hypnotic agent suggests adjunct non-pharmacologic measures, although a novel agent must be cross-checked to avoid drug-drug interactions and adjusted to renal and hepatic status.
Ivy should have proper directions as to the time frames and side effects that she should expect when starting or modifying antidepressants. Nausea, vomiting, diarrhea, headache, insomnia or somnolence, sexual dysfunction are common early adverse effects, which tend to resolve in four to six weeks (Edinoff et al., 2022). To minimize the risk of serotonin syndrome, she should not take alcohol and non-prescription drugs that have dextromethorphan or St. John Wort. Orthostatic dizziness can also happen and this is why she must not get up quickly after sitting. It is important to stress the compliance, even though the benefits may appear over time, to maximize the results. We can together work out a care plan by weighing the positive effects of each medication in mood and functioning against its side-effect profile and her history of health.
Describes Disease Pathophysiology Impact
In MDD, alterations start in the deepest parts of the brain where chemical messengers referred to as neurotransmitters, which include primarily serotonin, norepinephrine and dopamine, assist in regulating mood, energy, and motivation. Depression disrupts the balance and communication of the said chemicals, and this imbalance is coupled with hyperactivity of the stress-response system (the hypothalamic-pituitary-adrenal axis), which floods the body with cortisol (Ernstmeyer & Christman, 2022). Not only do such changes affect your thoughts, they also affect the autonomic nervous system (affecting heart rate and digestion of food), the endocrine system (the release of hormones), and even the immune system, which is why you may find yourself feeling more tired or physically achy.
As long as depression is not treated, you might observe that your mood will get deeper and deeper, and you will feel more tired and have problems with concentration. On a physical level, the constant elevated cortisol may cause chronic sleep disturbances, whether insomnia or oversleeping, and may interfere with your appetite and weight (Xu et al., 2022). Emotionally, you may become more irritable or disconnected with things that you enjoyed. This constant state of feeling in low gear will not only cause day to day tasks to be overwhelming but can also increase anxiety and a feeling of hopelessness over time.
These internal transformations are something you can see and explain. You can speak more slowly, you can not find a word, or you can take time between sentences. It would make your body heavy, stiff, and it would take a longer time to move and be less coordinated. You might find less interest in social activities, cancel plans or struggle to get out of bed in the morning. It is also possible to have headaches, stomach pain, or muscle pains without any clear medical cause (National Institute of Mental Health, 2024). Knowing that these effects are a natural reaction of the body to changes in chemicals and hormones as opposed to a weakness can assist you to know when you need to seek assistance and motivate you to persevere in treatment.
Care Priorities
The most important thing is to make Ms. Jackson safe and stable. This encompasses frequent screening of suicide risk and creation of a safety plan with collaboration (American Psychiatric Association [APA] practice guidelines) (Horowitz et al., 2023). Second, optimization of the pharmacotherapy, including the following: monitoring the efficacy and tolerability of escitalopram, early side effects, including gastrointestinal upset, insomnia, or hyponatremia, and adjusting the dose or considering augmentation by week 6 in case of insufficient improvement in mood (Parish et al., 2023). Third, the treatment of sleep disturbance and energy deficits by means of adjunctive nonpharmacologic interventions (e.g., sleep hygiene, structured activity scheduling) in addition to her meditation practice. Lastly, to address cognitive distortions and interpersonal stressors due to her divorce, the facilitation of evidence-based psychotherapy (CBT or IPT) is possible (Srivastava et al., 2024).
Integration of Assessment, Pharmacology, and Pathophysiology
The psychomotor slowing, weight loss, and the insomnia experienced by Ms. Jackson are symptoms of the monoamine dysregulation and hyperactivity of the HPA-axis that is symptomatic of major depressive disorders. Having attributed these outcomes to her history, hypertension on hydrochlorothiazide and lisinopril, and prior venlafaxine withdrawal, we had placed a worth on an SSRI that has a desirable cardiovascular and metabolic safety profile. Escitalopram has low P450 interactions, which reduce the risks of adverse drug-drug interactions and diuretic-associated hyponatremia (Chu & Wadhwa, 2025). Watching her symptom patterns and adverse effects closely follows the best practice in SSRI management, considering the fact that symptom improvement through normalization of neurotransmitters may take up to four to six weeks.
Evidence-Based Support
These priorities are supported by the APA recommendations on MDD, which focus on early safety evaluation and measurement-based care as the means of guiding treatment modifications. The American College of Physicians also recommended the use of SSRIs as the first-line medication in older adults because of their safety (Karrouri et al., 2021). The recommendations of Bartova et al. (2021) backed the combination of pharmacotherapy and structured psychotherapy to minimize the risk of relapse and enhance functional recovery. Our care plan is in line with the best current practices because it integrates the clinical picture of Ms. Jackson, her medication history, and her neurobiological processes to maximize outcomes and future well-being.
Conclusion
Ms. Jackson has major depressive disorder because of being persistently sad, anhedonia, weight loss, sleep disturbance, and psychomotor retardation following a separation in marriage. The normal levels of thyroid and vitamin D eliminate other causes. She has started taking escitalopram and has noticed some improvement in sleep early on and practices meditation. Such a gradual recovery will be promoted by constant monitoring of the symptoms, medication effects, and the initiation of evidence-based psychotherapy.
References
Bains, N., & Abdijadid, S. (2025). Major depressive disorder. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK559078/
Bartova, L., Fugger, G., Dold, M., Swoboda, M. M. M., Zohar, J., Mendlewicz, J., Souery, D., Montgomery, S., Fabbri, C., Serretti, A., & Kasper, S. (2021). Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder—Evidence from the European Group for the Study of Resistant Depression. Journal of Psychiatric Research, 141, 167–175. https://doi.org/10.1016/j.jpsychires.2021.06.028
Chu, A., & Wadhwa, R. (2025). Selective serotonin reuptake inhibitors. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK554406/
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024). Major depressive disorder: Hypothesis, mechanism, prevention and treatment. Signal Transduction and Targeted Therapy, 9, 30. https://doi.org/10.1038/s41392-024-01738-y
Edinoff, A. N., Raveendran, K., Colon, M. A., Thomas, B. H., Trettin, K. A., Hunt, G. W., Kaye, A. M., Cornett, E. M., & Kaye, A. D. (2022). Selective serotonin reuptake inhibitors and associated bleeding risks: A narrative and clinical review. Health Psychology Research, 10(4). https://doi.org/10.52965/001c.39580
Ernstmeyer, K., & Christman, E. (2022). Chapter 7 depressive disorders. In Nursing: Mental Health and Community Concepts [Internet]. Chippewa Valley Technical College. https://www.ncbi.nlm.nih.gov/books/NBK590047/
Nurs Fpx 4015 Assessment 5 Comprehensive Head-to-Toe Assessment
Horowitz, L. M., Ryan, P. C., Wei, A. X., Boudreaux, E. D., Ackerman, J. P., & Bridge, J. A. (2023). Screening and assessing suicide risk in medical settings: Feasible strategies for early detection. Focus, 21(2), 145–151. https://doi.org/10.1176/appi.focus.20220086
Karrouri, R., Hammani, Z., Benjelloun, R., & Otheman, Y. (2021). Major depressive disorder: Validated treatments and future challenges. World Journal of Clinical Cases, 9(31), 9350–9367. https://doi.org/10.12998/wjcc.v9.i31.9350
Kukucka, T., Ferencova, N., Visnovcova, Z., Ondrejka, I., Hrtanek, I., Kovacova, V., Macejova, A., Mlyncekova, Z., & Tonhajzerova, I. (2024). Mechanisms involved in the link between depression, antidepressant treatment, and associated weight change. International Journal of Molecular Sciences, 25(8). https://doi.org/10.3390/ijms25084511
Landy, K., Rosani, A., & Estevez, R. (2025). Escitalopram. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK557734/
National Institute of Mental Health. (2024). Depression in women: 4 Things to Know – National Institute of Mental Health (NIMH). https://www.nimh.nih.gov/health/publications/depression-in-women
Parish, A. L., Gillis, B., & Anthamatten, A. (2023). Pharmacotherapy for depression and anxiety in the primary care setting. The Journal for Nurse Practitioners, 19(4). https://doi.org/10.1016/j.nurpra.2023.104556
Srivastava, K., Chatterjee, K., Prakash, J., Yadav, A., & Chaudhury, S. (2024). Comparative efficacy of cognitive behavior therapy and interpersonal therapy in the treatment of depression: A randomized controlled study. Industrial Psychiatry Journal, 33(1), 160–167. https://doi.org/10.4103/ipj.ipj_294_23
Xu, G., Li, X., Xu, C., Xie, G., & Liang, J. (2022). Effect of insomnia in the major depressive disorder. BioMed Central Neurology, 22(1), 341. https://doi.org/10.1186/s12883-022-02869-x